Fortress Biotech Inc.
Fortress Biotech Inc. (FBIO): 13 pipeline candidates · 2 upcoming catalysts · ~49 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
49.0 months
D/E 0.95 · 16% dilution
Lead: Approved
13 candidates
2 upcoming, next in ~1669d
N/A
A transparent, data-derived signal for Fortress Biotech Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$102.0M
Cash
$257.1M
Quarterly Burn
$16.4M
Runway
49.0 mo
Revenue
$15.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| cael-101 | Phase 3 |
| cutx-101 | BLA Filed |
| emrosi | Approved |
| mb-101 | Phase 1 |
| mb-101 | Phase 1 |
| mb-108 | Phase 1 |
| mb-108 | Phase 1 |
| mb-109 | Phase 1 |
| triplex | Phase 2 |
| triplex | Phase 2 |
Showing 10 of 13 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
51
Total value held
$14.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,932,060 | $5.4M |
| susquehanna international group, llp | 506,645 | $1.4M |
| geode capital management, llc | 290,255 | $810K |
| northern trust corp | 230,053 | $642K |
| citadel advisors llc | 209,389 | $584K |
| blackrock, inc. | 197,085 | $550K |
| two sigma investments, lp | 196,825 | $549K |
| bridgeway capital management, llc | 182,368 | $509K |
| vanguard fiduciary trust co | 142,535 | $398K |
| kestra advisory services, llc | 129,801 | $362K |
Showing top 10 of 51 institutional holders of Fortress Biotech Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Fortress Biotech Inc.'s pipeline?
Fortress Biotech Inc. (FBIO) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Fortress Biotech Inc.'s lead drug candidate?
Fortress Biotech Inc.'s most advanced tracked candidate is cael-101 (Phase 3) for amyloid light chain ("AL") amyloidosis.
What is Fortress Biotech Inc.'s next catalyst?
Fortress Biotech Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZYCUBO" — expected January 12, 2031.
What is Fortress Biotech Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Fortress Biotech Inc. has approximately 49.0 months of cash runway.
What is Fortress Biotech Inc.'s market capitalization?
Fortress Biotech Inc.'s market capitalization is approximately $102.0M.
Get the full picture on Fortress Biotech Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.